Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IMPDH2 | P12268 | 16/20 | 0.72 |
| ▸ | AAK1 | Q2M2I8 | 4/20 | 0.72 |
| ▸ | IMPDH1 | P20839 | 4/20 | 0.63 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.60 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6495194 | 0.92 | IMPDH2 (0.84) | IMPDH2AAK1IMPDH1ROCK2ROCK1 | |
| SCHEMBL6486128 | 0.90 | IMPDH2 (0.74) | IMPDH2AAK1IMPDH1ROCK2ROCK1 | |
| SCHEMBL6501086 | 0.90 | IMPDH2 (0.77) | IMPDH2AAK1IMPDH1ROCK2ROCK1 | |
| SCHEMBL14518602 | 0.86 | IMPDH2 (0.83) | IMPDH2AAK1IMPDH1 | |
| SCHEMBL6496013 | 0.85 | IMPDH2 (0.74) | IMPDH2AAK1IMPDH1 | |
| SCHEMBL15741699 | 0.85 | IMPDH2 (0.81) | IMPDH2AAK1IMPDH1ROCK2ROCK1 | |
| SCHEMBL15741623 | 0.85 | IMPDH2 (0.81) | IMPDH2AAK1IMPDH1ROCK2ROCK1 | |
| SCHEMBL1475811 | 0.84 | IMPDH2 (1.00) | IMPDH2AAK1IMPDH1ROCK2ROCK1 | |
| SCHEMBL6486382 | 0.84 | IMPDH2 (0.70) | IMPDH2AAK1IMPDH1 | |
| SCHEMBL15741840 | 0.84 | IMPDH2 (0.80) | IMPDH2AAK1IMPDH1ROCK2ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050075499-A1 | Tricyclic compounds protein kinase inhibitors for enhancing the efficacy of anti-neoplastic agents and radiation therapy | AGOURON PHARMACEUTICALS, INC. | 2005-04-07 | — | — | US | disclosed |
| US-6867299-B2 | Inosine monophosphate dehydrogenase (IMPDH); use as immunosuppressants, anticancer agents and antiviral agents | HOFFMANN-LA ROCHE INC. (US) | 2005-03-15 | — | — | US | disclosed |
| US-20020052513-A1 | Oxamide IMPDH inhibitors | HOFFMANN-LA ROCHE INC. | 2002-05-02 | — | — | US | disclosed |
| EP-1127883-A2 | Oxamides as IMPDH inhibitors | F. HOFFMANN-LA ROCHE AG (CH) | 2001-08-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075499-A1 | Tricyclic compounds protein kinase inhibitors for enhancing the efficacy of anti-neoplastic agents and radiation therapy | CHEK2, CHEK1, CHKA | IMPDH2 4205/4885AAK1 154/4885IMPDH1 3742/4885 |
| US-20020052513-A1 | Oxamide IMPDH inhibitors | IMPDH1, IMPDH2, IMPA1 | IMPDH2 2/4885AAK1 2882/4885IMPDH1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.